Important Information
If you are interested in applying for this study, please:
- Read the study description and the study information document.
- Review the Visit Planner dates in your location and confirm that you are available for the stated dates.
- If you have not yet registered with us, click on the ‘Register’ button at the top of this page and answer the questions.
- If you have already registered with us, answer the pre-screening questions listed below and submit your interest.
We will then contact you to check your suitability.
Study Description
New Zealand Clinical Research is trialling an investigational medicine that could help people with Hypophosphatasia (HPP). HPP is a rare genetic condition that affects the development and strength of bones and teeth. In people with HPP, the body does not make enough of an enzyme which helps break down a natural substance called inorganic pyrophosphate (PPi). When PPi builds up in the body, it stops important minerals in teeth bones and teeth from hardening properly, and this leads to soft, fragile, and painful bones and teeth.
The medicine, ALE1, may help people with HPP by reducing the buildup of PPi, and it is hoped that this may be an effective treatment for HPP.
This is an investigational drug because it has not been approved by MedSafe or other drug regulatory authorities.
Requirements
Healthy Males and Females
- Aged between 18 – 50 years
- BMI (Body Mass Index) between 18 – 32 kg/m2
- Smokers/Vapers allowed (must refrain for the duration of the study)
- Not currently taking any regular prescription medications [or supplements]
What is Involved?
Study Visits: 1 x 4-night stay + 5 clinic visits
Reimbursement: Up to $3,100 before tax